Macmillan Cancer Support

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Oxford Cancer Analytics develops an AI-based platform for early cancer detection via blood testing. It analyzes liquid biopsy results from DNA, proteins, epigenetics, epidemiology, and medical history, enabling healthcare providers to identify cancers early and initiate curative treatment.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.

Leo Cancer Care develops an integrated cancer treatment system designed to simplify radiation therapy and improve patient experience. Founded in Australia, the company promotes upright patient positioning and a shift from machine rotation to patient rotation, supported by global research on its clinical benefits. The system combines three-dimensional imaging with automated control of radiation beams to deliver the appropriate energy to the targeted tissue, enabling radiotherapy centers to reduce pain, time, and cost. It can be integrated with standard radiotherapy equipment to support image-guided delivery and streamlined workflows. By prioritizing patient positioning and precise dose delivery, Leo Cancer Care aims to improve treatment accuracy, accessibility, and safety in cancer care.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.